Why the study?
Does dapagliflozin decrease epicardial adipose tissue volume and improve metabolic parameters in diabetes mellitus patients?
Does dapagliflozin decrease epicardial adipose tissue volume and improve metabolic parameters in diabetes mellitus patients?
Dapagliflozin may reduce epicardial adipose tissue volume and improve metabolic parameters in patients with diabetes mellitus, potentially contributing to cardiovascular risk reduction.
May support EAT reduction with dapagliflozin in diabetes; hypothesis-generating and requires randomized confirmation.
Treatment with dapagliflozin might improve systemic metabolic parameters and decrease the EAT volume in diabetes mellitus patients, possibly contributing to risk reduction in cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Sato et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: